Study shows how lesion morphology is associated with rates of recurrence.
Higher dietary intake of multiple nutrients may be associated with decreased progression of age-related macular degeneration.
Research used driving and reading to measure visual usefulness for patients with Wet AMD.
A new study reveals the incidence of late stage age-related macular degeneration by region and ethnicity.
Investigators uncover which patients are more likely to misidentify their treatment eye.
Researchers evaluate whether patients with central vision loss experience binocular advantage or disadvantage when reading.
Researchers found that, while patients who have a lapse in anti-VEGF injections can regain central subfield thickness after missing 12 months of visits, losses to visual acuity are permanent.
Researchers have identified structural changes to the macula that are not associated with functional visual changes in some patients.
Research recommends vitamins for patients at risk for age-related macular degeneration. But most on the market have lower concentrations than suggested, a new study shows.
Researchers unveil a new, comprehensive AMD prediction model. An interactive tool is now online for patients to gauge their risk.
An investigation uncovers the reasons behind the nearly 60% nonadherence and nonpersistence rate in patients with neovascular age-related macular degeneration after 24 months.
Variability in photoreceptor degeneration between eyes may be prognostic for future progression rates.
Investigators assessed whether patients undergoing treatment with anti-VEGF injections for age-related macular degeneration, diabetic retinal disease or retinal venous occlusive disease experienced side effects associated with therapy.
A study shows that behaviors associated with cardiovascular health can also help stave off ocular diseases, especially diabetic retinopathy.
The FDA has granted Fast Track designation to Zimura (avacincaptad pegol; Iveric Bio) for the treatment of geographic atrophy secondary to dry age-related macular degeneration.
Cases of severe vision loss, inflammation, and potential retinal vasculitis following treatment with Beovu (brolucizumab) injection are currently being investigated by the product’s manufacturer Novartis.